Boston, Mass. – September 2, 2020 – (BUSINESS WIRE) – Decibel Therapeutics, a clinical-stage biotechnology company developing novel gene therapeutics for restoration of hearing loss and balance disorders, today announced that Laurence Reid Ph.D., Chief Executive Officer of Decibel, will present at Citi’s 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 1:10pm ET.

About Decibel Therapeutics

Decibel Therapeutics is a clinical-stage biotechnology company focused on developing treatments that restore functional hair cells within the inner ear to treat disorders of hearing and balance. Leveraging industry-leading single-cell genomics capabilities and proprietary gene therapy technologies, Decibel has established the world’s first comprehensive research, discovery, and drug development platform aimed at restoring hearing and balance function. Decibel’s pipeline, including its lead gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program, is designed to deliver on our vision of a world in which the privileges of hearing and balance are available to all. For more information about Decibel Therapeutics, please visit or follow @DecibelTx.



Julie Seidel
Stern Investor Relations, Inc.